CEACAM5: An Emerging Therapeutic Target in Non-small Cell Lung Cancer

A comprehensive overview of the current landscape of non-small cell lung cancer (NSCLC), highlighting the impact of biomarkers on treatment selection.

The discussion centered around emergent biomarkers and targeted therapies in NSCLC, exploring targets like CEACAM5, TROP2, HER3, cMET, and the potential role of antibody drug conjugates in refractory disease.

The role of CEACAM5, its expression in NSCLC, and its potential as a therapeutic target are thoroughly examined, including its impact on tumorigenesis and prognosis in NSCLC patients.

Experts share their approach to CEACAM5 testing, including the testing procedure, patient selection criteria, and timing of testing.

Dr. Florez and Dr. Sabari discuss standards of care for different patient populations in NSCLC.

The transformative potential of antibody drug conjugates in NSCLC treatment is discussed, encompassing their design, bystander effect, biomarkers, and impact on the treatment landscape.

An overview of the CARMEN-LC03 and CARMEN-LC04 trials investigating tusa in different treatment settings for NSCLC and their impact on treatment approaches is provided.

Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.

Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.